Merck & Co. has stopped a trio of phase 3 blood cancer trials after one study suggested the benefits of the BTK inhibitor may ...
Isomorphic Labs has raised a $5 billion series C round, marking the second time in six months that the AI drug development ...
Beleaguered Kyntra Bio can’t catch a break. Formerly known as FibroGen, the company has endured a series of woes over the ...
Sellas Life Sciences’ cancer vaccine for acute myeloid leukemia (AML) has passed a phase 3 test with a more than nine-month ...
For some rare genetic diseases, the problem isn't a missing protein but the buildup of toxic molecules that the body can no ...
A new biotech targeting blood disorders, aptly called Marrow Therapeutics, has launched with $173 million in overall funding ...
Lilly is making an upfront payment and an equity investment in Stipple, although neither party has broken down the financials ...
CG now plans to complete that expanded FDA submission by the end of 2027’s first quarter. Meanwhile, in intermediate ...
TrimTech Therapeutics has been tapped by Biogen in a $411 million biobucks collaboration to develop protein degraders for ...
Johnson & Johnson has struck a deal to buy Ollin Biosciences for $2.2 billion upfront, establishing itself as a threat to ...
Eli Lilly has added another myelofibrosis (MF) play to its pipeline courtesy of a $1.5 billion deal for Massachusetts biotech ...
Chinese authorities have fired two researchers over their roles in the death of a child in a gene editing study, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results